LLY

734.37

-0.09%↓

JNJ

176.67

-0.01%↓

ABBV

208.05

-0.2%↓

UNH

303.9

+1.02%↑

AZN

79.94

-0.17%↓

LLY

734.37

-0.09%↓

JNJ

176.67

-0.01%↓

ABBV

208.05

-0.2%↓

UNH

303.9

+1.02%↑

AZN

79.94

-0.17%↓

LLY

734.37

-0.09%↓

JNJ

176.67

-0.01%↓

ABBV

208.05

-0.2%↓

UNH

303.9

+1.02%↑

AZN

79.94

-0.17%↓

LLY

734.37

-0.09%↓

JNJ

176.67

-0.01%↓

ABBV

208.05

-0.2%↓

UNH

303.9

+1.02%↑

AZN

79.94

-0.17%↓

LLY

734.37

-0.09%↓

JNJ

176.67

-0.01%↓

ABBV

208.05

-0.2%↓

UNH

303.9

+1.02%↑

AZN

79.94

-0.17%↓

Search

Essa Pharma Inc

Uždarymo kaina

0.21 -19.23

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

0.21

Max

0.26

Pagrindiniai rodikliai

By Trading Economics

Pajamos

2.4M

-4M

Pelnas, tenkantis vienai akcijai

-0.14

Dividendų pajamingumas

87.56

Pelno marža

-4,681.422

Darbuotojai

35

EBITDA

1.4M

-5M

Dividendai

By Dow Jones

Dividendų pajamingumas

Sektoriaus vid.

87.56%

2.38%

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

-48M

37M

Ankstesnė atidarymo kaina

19.44

Ankstesnė uždarymo kaina

0.21

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Bearish Evidence

Essa Pharma Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-08-26 23:56; UTC

Uždarbis

WiseTech Lifts Dividend as Its Annual Profit Rises 30% -- Update

2025-08-26 23:48; UTC

Uždarbis

Woolworths Annual Profit Falls, Cuts Dividend

2025-08-26 23:41; UTC

Uždarbis

WiseTech Lifts Dividend as Its Annual Profit Rises 30%

2025-08-26 23:58; UTC

Uždarbis

China Resources Land: Real-Estate Sector Faces Structural Challenges, but Homebuying Demand Gradually Returning >1109.HK

2025-08-26 23:57; UTC

Uždarbis

China Resources Land: 1H Results Buoyed by Investment Property & Asset Management Business >1109.HK

2025-08-26 23:55; UTC

Uždarbis

China Resources Land 1H Net CNY11.88B Vs. Net CNY10.22B >1109.HK

2025-08-26 23:55; UTC

Uždarbis

China Resources Land 1H Rev CNY94.92B Vs. CNY79.19B >1109.HK

2025-08-26 23:48; UTC

Uždarbis

Karoon Energy Interim Dividend 2.4 Australian Cents/Security

2025-08-26 23:47; UTC

Uždarbis

Karoon Energy 1H Underlying Net Profit US$45 Million, Down 61% on Year

2025-08-26 23:47; UTC

Uždarbis

Karoon Energy 1H Revenue US$308.3 Million, Down 25% on Year

2025-08-26 23:47; UTC

Uždarbis

Karoon Energy 1H Net Profit US$71 Million, Up 15% on Year

2025-08-26 23:46; UTC

Rinkos pokalbiai

Nikkei May Trade in Range Amid US Tariff Uncertainty -- Market Talk

2025-08-26 23:42; UTC

Rinkos pokalbiai

Gold Edges Lower on Possible Position Adjustments -- Market Talk

2025-08-26 23:35; UTC

Uždarbis

Karoon Energy Expects Expenditure of US$80 Million-US$90 Million Over 2030-2034

2025-08-26 23:35; UTC

Uždarbis

Karoon Energy Expects Expenditure of US$55 Million-US$65 Million for Projects in 2026

2025-08-26 23:34; UTC

Uždarbis

Karoon Energy: Baúna Revitalization, Life Extension Projects Initiated

2025-08-26 23:34; UTC

Uždarbis

Karoon Energy: Baúna Project Economic Field Life Extends to 2039

2025-08-26 23:33; UTC

Uždarbis

Karoon Energy Raises Baúna Project 2P Reserves by 13.7 Million Bbls

2025-08-26 23:23; UTC

Uždarbis

WiseTech: FY25 Ebitda Margin Exit Run Rate 52%>WTC.AU

2025-08-26 23:22; UTC

Uždarbis

WiseTech: New CargoWise Commercial Model Ready for Rollout>WTC.AU

2025-08-26 23:21; UTC

Uždarbis

WiseTech Says Integration of e2open Is on Track>WTC.AU

2025-08-26 23:14; UTC

Uždarbis

WiseTech Expects FY26 Ebitda Margin of 40-41%>WTC.AU

2025-08-26 23:13; UTC

Uždarbis

WiseTech Expects FY26 Ebitda Growth of 44-53%>WTC.AU

2025-08-26 23:13; UTC

Uždarbis

WiseTech Expects FY26 Ebitda of $550M-$585M>WTC.AU

2025-08-26 23:13; UTC

Uždarbis

WiseTech Expects FY26 Revenue Growth of 79-85%>WTC.AU

2025-08-26 23:12; UTC

Uždarbis

WiseTech Expects FY26 Revenue of $1.39B-$1.44B>WTC.AU

2025-08-26 23:11; UTC

Uždarbis

WiseTech FY Ebitda Margin Ex-e2open Costs 53%>WTC.AU

2025-08-26 23:11; UTC

Uždarbis

WiseTech FY Ebitda Margin 49% Vs. 48%>WTC.AU

2025-08-26 23:10; UTC

Uždarbis

WiseTech FY Ebitda $381.6M Vs. $325.0M>WTC.AU

2025-08-26 23:09; UTC

Uždarbis

WiseTech Global Declares Dividend of $0.077 >WTC.AU

Akcijų palyginimas

Kainos pokytis

Essa Pharma Inc Prognozė

Bendras įvertinimas

By TipRanks

0 ratings

0

Pirkti

0

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

1.7 / 1.72Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Bearish Evidence

Vidutinės trukmės periodas

Bullish Evidence

Ilgalaikis periodas

Weak Bearish Evidence

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Essa Pharma Inc

ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses the development of small molecule drugs for the treatment of prostate cancer. The company's lead candidate EPI-7386, an androgen receptor based resistance mechanisms that develop in patients with castration-resistant prostate cancer and metastatic castration-resistant prostate cancer. It has collaboration agreements with Bayer Consumer Care AG; Janssen Research & Development, LLC; and Astellas Pharma Inc. ESSA Pharma Inc. was incorporated in 2009 and is headquartered in Vancouver, Canada.